Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases. Dig Dis,2017,35(3):288-292.Halilbasic E, Steinacher D, Trauner M. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases. Dig Dis 2017; 35: 288...
Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin. Sci. (Lond.) 121 (12), 523-544.Roma MG, Toledo FD, Boaglio AC, et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 2011;121:523-44....
Ursodeoxycholic acid;Ursodesoxycholic acid;3α,7β-Dihydroxy-5β-cholan-24-oate;3α,7β-Dihydroxycholanic acid;3α,7β-Dihydroxy-5β-cholanic acid;3α,7β-Dihydroxy-5β-cholanoic acid;7β-Hydroxylithocholic acid;3α,7β-Dihydroxy-5β-cholan-24-oic acid;Urso;Actigall;Ursodiol;Deursil;...
Paumgartner G, Beuers U: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002 Sep;36(3):525-31. doi: 10.1053/jhep.2002.36088. [Article] Angulo P: Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Re...
Ursodeoxycholic acid (UDCA), initially introduced as a therapeutic approach to counteract the cholestatic components to PBC and PSC, was subsequently shown to exhibit unexpected anti-inflammatory and immunomodulatoty properties. The use of farnesoid X receptor (FXR) and TGR5 agonists in various animal...
Ursodeoxycholsäure; Acide ursodésoxycholique; Ácido ursodesoxicólico; 우르 소데 옥시 콜산; ウルソデオキシコール酸; (3α,5β,7β)-3,7-Dihydroxycholan-24-oic acid; (4R)-4-[(3R,5S,7S,8R,9S,10R,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,...
The immunomodulatory effects of ursodeoxycholic acid are believed to involve decreased immunoglobulin production by B lymphocytes, decreased interleukin-1 and -2 production by T lymphocytes, decreased expression of hepatocyte cell surface membrane HLA class I molecules and possibly stimulation of the hepatocy...
Therapeutic effect of ursodeoxycholic acid on chronic hepatitis C with cholestatic cirrhosis: Ashraf R Abul-Futuh MD, Mansoura International Hospital, Mansoura Egypt; Salwa M El Hadad, Ain Shams Univ Hosp Egypt, Cairo Egypt; Abdel Ghani M Solayman, Asiut University Hosp Egypt, Asiut Egypt; ...
The concentration of ursodeoxycholic acid in bile increased in a dose-dependent manner. When the dose is 20~30mg/(kg d), the concentration in bile exceeds 60%, which can achieve the best therapeutic effect. In the liver, it is combined with glycine, taurine, etc., and is metabolized by...
A side-chain shorted derivative of ursodeoxycholic acid (UDCA) is 24 nor-ursodeoxycholic acid (NorUDCA) and it represents a new class of drugs for treatment of liver diseases. NorUDCA has unique biochemical and therapeutic properties, since it is relatively resistant to conjugation with glycine or...